Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol

INTRODUCTION: The Global Platform for the Prevention of Autoimmune Diabetes-SINT1A Study is designed as a randomised, placebo-controlled, double-blind, multicentre, multinational, primary prevention study aiming to assess whether daily administration of Bifidobacterium infantis from age 7 days to 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziegler, Anette-Gabriele, Arnolds, Stefanie, Kölln, Annika, Achenbach, Peter, Berner, Reinhard, Bonifacio, Ezio, Casteels, Kristina, Elding Larsson, Helena, Gündert, Melanie, Hasford, Joerg, Kordonouri, Olga, Lundgren, Markus, Oltarzewski, Mariusz, Pekalski, Marcin L, Pfirrmann, Markus, Snape, Matthew D, Szypowska, Agnieszka, Todd, John A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578987/
https://www.ncbi.nlm.nih.gov/pubmed/34753762
http://dx.doi.org/10.1136/bmjopen-2021-052449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578987/
https://www.ncbi.nlm.nih.gov/pubmed/34753762
http://dx.doi.org/10.1136/bmjopen-2021-052449

Ejemplares similares